Mehmet Bilen is an Oncology physician affiliated with Emory Healthcare. OpenAlex indexes 729 publications with 12,357 citations (h-index 50); ClinicalTrials.gov lists 6 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Winship Cancer Institute Of Emory University
1365c Clifton Road
Atlanta, GA 303220001
Telephone
404-778-1900Registry record last updated 30 Jun 2016.
Clinical trials
- Testing the Investigational Medication Pembrolizumab After Kidney Removal for Patients With Non-Clear Cell Renal Cell Carcinoma
Sponsor: National Cancer Institute (NCI)
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
17 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Janssen Scientific Affairs, LLCProgram year20253 payments$17,740openpaymentsdata.cms.gov ↗
- Exelixis Inc.Program year20254 payments
- PFIZER INC.Program year20252 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
50.4%Kinase inhibitor15.9%Cabometyx54%Inlyta33%Lenvima8%Sunitinib Malate5%Part D<11 patientsCytochrome P450 17A1 Inhibitor11.7%Abiraterone Acetate100%Part D≥37 patients+ 4 more classes in this area
Metabolism & gastrointestinal
20.5%Corticosteroid15.2%Prednisone100%Part D≥54 patientsSerotonin-3 Receptor Antagonist2.8%Ondansetron Hcl100%Part D≥26 patients+ 2 more classes in this area
Nervous system
10.5%Opioid Agonist3.7%Tramadol Hcl59%Oxycodone Hcl41%Part D≥19 patientsGabapentinoids3.1%Gabapentin100%Part D≥17 patients+ 3 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma
New England Journal of Medicine
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Allan Levey, MD, PhD
Emory Healthcare
William Blum, MD
Emory Healthcare
Bradley Leshnower, MD
Emory Healthcare
Stephen Pastan, MD
Emory Healthcare
Carl June, MD
University of Pennsylvania
Christopher Benz, MD
Buck Institute for Research on Aging
Christina Fitzmaurice, MD
Gundersen Health System
Beth Karlan, MD
Cedars-Sinai Medical Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”